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human infection model for cutaneous
leishmaniasis
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Abstract
Background: A controlled human infection model (CHIM) involves deliberate exposure of volunteers to pathogens
to assess their response to new therapies at an early stage of development. We show here how we used public
involvement to help shape the design of a CHIM to support future testing of candidate vaccines for the neglected
tropical disease cutaneous leishmaniasis, a disease transmitted by the bite of infected sand flies in tropical regions.
Methods: We undertook a public involvement (PI) consultation exercise to inform development of a study to test
the safety and effectiveness of a sand fly biting protocol using uninfected sand flies (FLYBITE: ClinicalTrials.gov ID
NCT03999970) and a CHIM using Leishmania major-infected sand flies (LEISH_Challenge: ClinicalTrials.gov ID
NCT04512742), both taking place in York, UK. We involved 10 members of the public including a patient research
ambassador and a previous CHIM volunteer. The session took place at The University of York, UK and examined
draft study volunteer-facing material and included the CHIM study design, potential adverse events and therapeutic
interventions at study endpoints. A discussion of the scientific, ethical, humanitarian and economic basis for the
project was presented to the participants to provoke discourse. An inductive, thematic analysis was used to identify
the participants’ key concerns.
Results: Themes were identified relating to i) quality of volunteer-facing written information, ii) improving study
design, and iii) factors to motivate involvement in the research. Group participants responded positively to the
overall study aims. Initial concerns were expressed about potential risks of study involvement, but further
explanation of the science and mitigations of risk secured participant support. Participants provided advice and
identified improved terminology to inform the volunteer-facing material. Lastly, treatment options were discussed,
and excision of any cutaneous lesion was favoured over alternatives as a treatment.
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Conclusion: The consultation exercise provided invaluable information which led to improved study design and
enhanced clarity in the volunteer-facing material. The session also reinforced the need to maintain public trust in
scientific rigour prior to initiation of any study. The investigators hope that this description strengthens
understanding of PI in clinical research, and encourages its use within other studies.
Plain English summary
Our research team is designing a type of research study known as a controlled human infection model (CHIM). In
CHIM studies, volunteers are exposed to infections on purpose and then studied to help understand diseases.
Similar experiments, where humans are infected deliberately, have been used for hundreds of years to help test
treatments. CHIM studies have already been used more recently to help test vaccines for diseases such as malaria.
The disease leishmaniasis, a disease affecting millions each year, is spread by the bite of an infected sand fly in
tropical countries. There are currently no vaccines for leishmaniasis that are available for use in humans. It is
thought that by using CHIM studies, new vaccines might be tested and then approved more quickly. Scientific
researchers have had many discussions about how useful CHIM studies are, especially in terms of the science
behind them, the safety of volunteers and the ethics of these studies. Researchers also understand how important
it is to involve the public in designing and carrying out research, especially studies involving humans, to get an
independent point-of-view. We have therefore involved the public, in some parts of designing this research, in a
group discussion. We also included a person who has already taken part in a different CHIM study. These
discussions have had an important effect and have changed how we plan to carry out our future research studies.
We also hope that this description will encourage other researchers to include the public when planning future
research.
Keywords: Controlled human infection model (CHIM), human challenge, Cutaneous leishmaniasis, Leishmania,
Clinical study, Public involvement, PI, Expectations, Qualitative research
Key lessons
 Controlled human infection models are not well
known to the public, and it is important to educate
the public in general as potential participants in
research.
 Clarity of written and verbal information for
volunteers is imperative in clinical research.
 The public representatives preferred excision biopsy
over other treatment modalities. This stimulated
discussion with clinical specialists and a consensus
opinion was formed for this approach. This is a
significant change to the project methodology
influenced by the public involvement process.
 Research conducted in the UK may not always
accurately reflect stakeholders in other countries.
 There is a longstanding issue with diversity amongst
research participants that is difficult to address.
 It is important to engage with technology (including
social media) to both attract potential volunteers,
but also to ensure engagement is maintained once a
study commences.
 Public involvement is imperative to good clinical
research as participants may add more holistic
viewpoints that are not limited by the inherent bias
of researchers.
Background
The recognition of the concept of patient-centred care
has proliferated since the mid-twentieth century [1]. The
model for a patient-centred approach then progressed
over the years, and has now become embedded within
healthcare policy in the UK. With this focus on patient-
centred healthcare, the discussion on stakeholder in-
volvement in care has also moved to include research
and clinical studies, with research being deemed integral
to good healthcare. The consensus is therefore that
high-quality research is dependent on public involve-
ment [2].
Public involvement (PI) and engagement has been sup-
ported in recent years by both allocation of research
funding specifically for PI activities and also by the cre-
ation of advisory bodies such as INVOLVE, championing
public involvement initiatives and supported by the Na-
tional Institute for Health Research (NIHR). The UK
National Health Service (NHS) Health Research
Authority has also published ‘The UK Policy Framework
for Health and Social Care’ in conjunction with
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INVOLVE, which addresses public involvement in re-
search including its remit in ethical review of studies [3,
4]. In addition, it has been demonstrated that public in-
volvement at an early stage of study development bene-
fits study design, increases recruitment and helps deliver
high-quality research [5]. The benefits of PI, in introdu-
cing a more inclusive and collaborative approach to in-
crease the quality of research, are well described [5].
This can result in more relevant and pragmatic research,
that bridges the gap between researchers and the public,
and can result in novel aspects to the research focus.
This can occur through stimulating new discussions and
by adding a unique viewpoint which can raise issues not
previously anticipated by researchers [6, 7]. Extrapolat-
ing from this, there is some evidence to suggest PI may
improve patient-facing materials as well as research liter-
acy [7, 8]. As such, accountability for research studies
can be strengthened, with the potential to involve re-
search volunteers in this process [9]. It has also been
postulated that research studies can become more cost-
effective in the long-term as a result of PI [10].
We therefore describe here how our proposed research
into the development of a controlled human infection
model (CHIM), for the infectious disease leishmaniasis,
was shaped by public involvement. This took the form
of a PI consultation group session conducted by the re-
search team at The University of York, with participants
recruited from the UK. The terminology around stake-
holder involvement in research is inconsistent, however
we have adopted the use of the phrase ‘public involve-
ment’ given its adoption by NIHR as evidence by the UK
Standards for Public Involvement, following consultation
in 2017 [4]. Furthermore, our PI group consisted of
non-patient participants, and therefore the phrase ‘pa-
tient-public’ does not accurately reflect the background
of our participant group.
A solution being adopted for many diseases, which our
research team plan to adopt for leishmaniasis, is to de-
velop a ‘human challenge model’ also called a ‘controlled
human infection model’ (CHIM). This approach involves
deliberate exposure of individuals to an infection, in a
controlled setting, to better understand the disease and
to test potential vaccines and treatments. There has been
much ethical discussion of CHIM studies given the na-
ture of deliberate infections [11]. The Hippocratic Oath
has been quoted as a barrier to such studies, particularly
with regard to a chequered history of deliberate infection
in research in the early part of the twentieth century.
During their refinement over the last 20 years, CHIM
studies have contributed vital scientific knowledge that
has led to advances in the development of drugs and
vaccines [11, 12].
Leishmaniasis is listed by the World Health Organisa-
tion as a major neglected disease of poverty, affecting
populations in low and middle-income countries
(LMICs). It affects around 150 million people in 98
countries worldwide and is transmitted by a sand fly vec-
tor. To date there have been no autochthonous cases of
leishmaniasis in the UK, although there have been a
number of cases reported in some European regions
[13]. It has been reported however in return travellers to
the UK [14]. There are many species of Leishmania
widely dispersed geographically and different species
may cause disease that is manifest in the skin (tegumen-
tary leishmaniasis) or the internal organs of the body
(visceral leishmaniasis). The clinical spectrum of tegu-
mentary leishmaniasis ranges from localised, usually self-
healing, sores that result in a scar, (localised cutaneous
leishmaniasis; LCL), to more widespread diffuse or dis-
seminated disease. LCL scars can cause stigma, and dis-
proportionately affect children. There are several drug
treatments available to treat leishmaniasis, however vari-
ous factors have limited their effectiveness including
drug resistance, difficulty of use in LMICs, significant
side effect profile and limited effectiveness of vector con-
trol programmes. New treatments and vaccines are ur-
gently needed, but to date no vaccines have been
approved. This development process would be im-
mensely strengthened if there was a rapid, standardised
method for the early evaluation of the efficacy of candi-
date vaccines. Deliberate exposure of humans to infec-
tious pathogens has been studied as a method for better
understanding disease and infection for several hundred
years. More recently a similar approach has been used to
investigate diseases where a deliberate infection would
be beneficial in either better understanding a disease or
to test potential therapies [15], including diseases as di-
verse as influenza [16], norovirus [17], malaria [18] and
dengue [19]. Here, we describe how public involvement
has helped shape the development of a CHIM for sand
fly transmitted leishmaniasis. It is well known that sand
fly transmission potentiates infectivity of Leishmania
[20]. In addition, in experiments with Leishmania vac-
cines, it has been observed that these vaccines may be
protective in mice that have been infected with Leish-
mania via needle, but may fail to protect mice infected
with Leishmania via the natural sand fly vector [21]. As
such a model resembling the natural infection in the
wild, is needed to robustly test vaccines. Hence, our
public involvement discussions covered issues related to
the use of sand fly bite as a means of initiating leishman-
iasis as well as leishmaniasis per se.
Methods
Project overview
To develop a CHIM for cutaneous leishmaniasis, a series
of enabling studies (Stage 1) are required prior to the
conduct of human infection studies (Fig. 1):
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(i) a public involvement (PI) consultation group
exercise which we describe here in detail,
(ii) development of a suitable challenge agent
manufactured at Good Manufacturing Practices
(GMP), described in detail elsewhere [22],
(iii)development of a protocol for sand fly bites on
humans using pathogen-free sand flies (FLYBITE;
ClinicalTrials.gov ID NCT03999970),
(iv) a focus group discussion at the end of the FLYBITE
study.
Stage 2 of the project is a controlled human infection
study for cutaneous leishmaniasis in healthy volunteers,
(LEISH_Challenge; ClinicalTrials.gov ID NCT04512742),
followed by a further focus group.
Recruitment and PI consultation group location
Ethical approval for the PI consultation group conduct
and all material (PI participant consent form, plain Eng-
lish summary, protocol, agenda, draft FLYBITE and LEIS
H_Challenge volunteer advertisement/volunteer infor-
mation leaflets) was successfully obtained from the De-
partment of Biology Ethics Committee, University of
York (Ethics reference PK201812). Ethical approval from
the NHS Research Ethics Committee was not deemed
necessary as outlined by the NHS Health Research Au-
thority decision tool [23] and according to INVOLVE
guidance [24]. Therefore prior to the FLYBITE study, a
PI consultation group with participants recruited widely,
was carried out to make clinical investigators aware of
the public perception of human challenge models as well
as to inform the study design. The PI consultation group
activity has been reported in this manuscript in accord-
ance with the Guidance for Reporting Involvement of
Patients and the Public (GRIPP2) reporting checklist
[25] [see Additional file 2].
Participants were recruited to the PI consultation
group through local and national advertisements includ-
ing via patient advocate groups and University mailing
lists. Participants interested in taking part in the PI con-
sultation group were invited to make contact with the
project team. Then, after an initial discussion, those
participants who were interested were invited to attend.
A total of 10 participants were recruited, 7 female and 3
male. They included student and staff volunteers from
the University of York from a range of Science and Arts
backgrounds, a previous CHIM volunteer from a UK
centre, a previous vaccine study volunteer from a UK
centre, a patient research ambassador, and lay volunteers
from the local community. 6 participants were university
educated, with 5 of these participants having undertaken
further education in science fields. 5 participants were in
current employment, and 4 participants were full-time
students. Although age and ethnicity were not specific-
ally recorded, the research team did note a lack of ethnic
diversity amongst participants. All participants received
remuneration to the value of £75 following their attend-
ance, in addition to travel expenses. The remuneration
was based on INVOLVE and NIHR guidance which was
developed in conjunction with the UK Department of
Health [26, 27]. Participants were fully consented for
their involvement including for audio recording of pro-
ceedings and use of content in academic outputs. The
consultation exercise took place over the course of 3 h,
with all 10 participants present, and prior to ethical re-
view of the interventional human studies. No patients
previously treated for leishmaniasis were available for re-
cruitment to the PI consultation group.
The PI consultation group took place at the University
of York in February 2019 and was chaired by GJ, acting
as an independent facilitator. Clinical team members
were present for an initial summary of the project, in-
cluding the chief investigator (CJL) and principal investi-
gators (VP, AML). The clinical team then left the room
to allow discussion between participants and the inde-
pendent facilitator. Sample materials for the proposed
project were provided in advance in order for partici-
pants to digest the information and judge the studies in-
dependently. In total, four documents were provided: a
volunteer information leaflet for an uninfected sand fly
biting study (FLYBITE), a volunteer information leaflet
for a Leishmania CHIM (LEISH_Challenge), a plain
English summary of the overall project and an advertise-
ment poster for recruitment of volunteers.
Fig. 1 Schematic overview of incorporation of public involvement activities in the LEISH_Challenge project
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Key roles of PI consultation group participants out-
lined in communication prior to attendance were to: i)
consider the draft study protocols to identify any issues;
ii) ensure that the designs of the clinical studies are opti-
mal; iii) consider the ethical issues relating to the study;
iv) consider the plain English summary of the project;
and v) consider recruitment to the studies, and the feasi-
bility of the inclusion criteria.
The content of the consultation exercise was guided
by an initial presentation given by the clinical team on
the overall aims of the CHIM study and the specific fea-
tures of the disease, its treatment and current status
within world health.
Approach to data collection methodology
To structure the discussion, the initial plan was for a
simple presentation to be given by the clinical investiga-
tors and then for the discussion to be held entirely be-
tween the independent facilitator and the PI
consultation group participants, with the clinical investi-
gators to be present to clarify any points arising. How-
ever, given the complex and unique nature of the LEIS
H_Challenge study, the prior research participation ex-
perience of some participants and the culture of open-
ness and flexibility encouraged of participants, it
transpired that participants wished to ask pertinent
questions at each stage of the presentation. As such the
format evolved to one where a particular aspect was pre-
sented, during which participants were able to interact
with, and pose questions to, the clinical investigators.
The independent facilitator then expanded the discus-
sion at opportunistic time points both during and after
each topic presentation as appropriate. Subsequent to
this, the clinical team members left the room to allow
open discourse between the participants and the inde-
pendent facilitator. The agenda was not strictly adhered
to in order to facilitate free-flowing discourse. Any
topics not fully covered in the course of the consultation
exercise were then addressed at the end of the session.
Participants were also asked to voluntarily provide feed-
back at a later date, in an anonymous fashion if required,
although this was not universally carried out.
Analysis
The PI group session audio recording was fully tran-
scribed verbatim by a colleague external to the study
team. A qualitative thematic approach to data analysis
was employed, using the methodology and processes ad-
vocated by Braun and Clarke [28], and assisted via the
use of NVivo Pro software version 12 (QSR International
Pty Ltd). The use of qualitative analysis software can, if
used appropriately, facilitate data management, analysis
and analytic rigor [29].
The research team present at the session included
clinical team members (VP, CJ, AL), project manager
(EG), and GJ who was the PI consultation group inde-
pendent facilitator. CJ and AL have many years’ of ex-
perience with large clinical research studies, including
vaccine studies and studies involving leishmaniasis. They
both have some prior experience of PI within the devel-
opment of these studies. VP is an early career researcher
working on the project as a clinical research fellow, with
a background as an infectious disease clinician and ex-
perience in treating cases of leishmaniasis in return trav-
ellers to the UK. GJ has several years’ experience as a
health psychologist including significant experience with
running PI groups and using PI in clinical research. PK
is the senior scientific research lead for the project, and
conceived the overall project, as well as having under-
taken significant leishmaniasis research for many years.
NM has several years’ experience as a qualitative health
researcher and undertook transcription and coding of
the transcript. MS is a participant from the PI consult-
ation group who contributed to critical review of the
manuscript and advised on the participant experience.
PK and NM were not present during the consultation
group.
Several team members were involved in the data ana-
lysis, independently listening to the audio-recording and
reading the transcript several times (VP, GJ, NM), before
coding, at a semantic level, was undertaken to identify
and label the interesting items in the data (NM). A sec-
ond member of the team independently checked a pro-
portion of coding against the transcript (GJ). Together,
and in an iterative process, they actively searched for
and discussed where codes clustered together to develop
the themes. In a further review of these themes, key
themes and subthemes were generated and discussed
with VP and the wider study team.
Thematic analysis is a highly flexible approach that can
be used for engaging with, identifying and analysing the
meanings inherent within qualitative data. The aim of this
public involvement group was very much embedded within
applied health research, with a straight-forward goal of
summarising and interpreting the PI participants’ feedback
and comments concerning the draft study volunteer-facing
materials (including issues around study design, recruit-
ment, feasibility, inclusion criteria, ethical issues, and the
plain English summary). Therefore, an inductive (data-
driven) approach to coding and analysis was undertaken to
identify and prioritise the participants’ key concerns and
generate the themes following, in a non-linear process, the
six key stages that Braun and Clarke recommend [28].
Results
All 10 participants were present for the duration of the
PI consultation group discussion, which took place over
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the course of 3 h. Three clinical researchers were present
during the discussion (CJL, AML, VP), as described in
Methods. From the analysis, three overarching themes
were generated relating to i) the quality of the
volunteer-facing written information, ii) how to improve
the study design of both the uninfected sand fly biting
study (FLYBITE) and the CHIM study (LEISH_Chal-
lenge), and iii) factors to motivate involvement in the re-
search. The themes and their sub-themes, with
supporting exemplar quotes, are provided in
Additional File 1.
Overarching theme 1: The quality of the volunteer-facing
written information
This theme reflects on the participants’ perceived im-
portance of the quality of the volunteer-facing material,
in order to facilitate recruitment and engagement with
the study. This overarching theme had three embedded
themes: i) The need for clarity, ii) Consideration of the
visual material used, iii) Consideration of written
content.
The need for clarity
The participants described how further clarity was
needed in the written volunteer-facing materials espe-
cially in relation to the extent of the health screening,
length and number of study visits, and time involved
versus remuneration. Clarity was also sought regarding
inclusion and exclusion criteria, the comparative size of
the parasite and sand fly, the size of possible scarring
post-sand fly biting, anaphylaxis reaction in relation to
the species of sand fly and its management, the burden
of disease, and the number of sand flies and potential
bites. One participant described a brief internet search
of sand fly reactions as an example of the need for
clarity:
P7: Because I just Googled sand fly anaphylaxis and
found Zane Mirfin writing about people, you know, I
mean those aren’t the sand flies you’re using and it
is completely anecdotal but if somebody’s looking at
this and they could do exactly that, Google ‘sand fly’
and ‘anaphylaxis’ it does pull up anecdotes.
P9: You need to be clear that with this strain [of
sand fly], with this one, these things are not, there is
no recorded incidence of that [recurrence] happen-
ing. You need to be really clear.
Additional areas requiring clarity related to the details of
the FLYBITE study, including the quality of the sand fly
and any possibility of transmissible infections from an
‘uninfected’ sand fly. PI consultation group participants
also suggested for the eligibility requirements for LEIS
H_Challenge to be included in the initial FLYBITE study
materials, in order to provide as much information for
volunteers as possible. For the volunteer-facing informa-
tion for the LEISH_Challenge study, the areas requiring
clarity were the chances of contagion, infection and im-
munity, the treatment options available, and access to
out-of-hours support. Suggestions regarding language
choice and format of written information were also
raised, as described by one participant:
P7: And I think another thing with the literature
was making it clear what the actual sort of, like the
burden of the disease is. That it is this awful disfig-
uring disease you know and that’s what we want to
stop. You’re not going to be getting that disease.
What you’re doing is developing a model to study it
…
Further discussions around the specific terminology con-
cerned the description of the biting process:
P7: … saying you’re going to have a feeding chamber
strapped to your arm just sounds a little bit sinister.
P2: I think feeding sounds a bit off-putting.
P7: Biting doesn’t sound so bad because they are go-
ing to be biting you.
Consideration of the visual material used
This relates to images that may be provided of the sand
fly, images of the cutaneous leishmaniasis lesion, and an
example of the generalised scarring associated with an
uninfected sand fly bite. These images were discussed as
part of future advertisement and recruitment strategies,
in order to provide clarity for potential volunteers, as de-
scribed by one participant:
P9: … it would be helpful if you put a photo to show
of [the scar] afterwards.
Consideration of the written content used
The inclusion of significant amounts of General Data
Protection Regulation (GDPR) literature with informa-
tion leaflets was raised. Participants voiced whether this
could be condensed, and a link provided to more de-
tailed GDPR resources (for example a weblink) in order
to save time and reader fatigue. A discussion also took
place regarding the inclusion of a plain English summary
within the information leaflet itself and avoidance of sci-
entific jargon. It was also suggested that the contribution
to scientific knowledge should be emphasised within
volunteer-facing material, as described by one
participant:
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P9:… when you talk about the potential benefits of
the study I think you need to add on that one of the
potential benefits is you get to make a contribution,
you get to make a difference in helping us create a
model that will develop a vaccine that will change
and possibly save lives.
Overarching theme 2) how to improve the study design
(relating to FLYBITE and LEISH_Challenge studies)
A prolonged discussion of the various treatment options
for cutaneous leishmaniasis took place between clinical
investigators and PI consultation group participants. The
discussion centred around the evaluation of preferred
‘bite site’ as well as existing treatment options including
tablet, topical (typically creams and ointments), intra-
lesional (that is, injected at the site of a cutaneous leish-
maniasis lesion), intravenous therapies, cryotherapy, heat
therapy and surgical excision. Treatment(s) would be ne-
cessary in the LEISH_Challenge study, but not the FLY-
BITE study.
This overarching theme had six embedded themes: (i)
Alternative suggestions for volunteer engagement, (ii)
ways to improve recruitment, (iii) suggestions for choice
of bite location, (iv) choice of treatments (LEISH_Chal-
lenge study only), (v) informing the volunteers’ General
Practioners (GPs) about their participation, and (vi)
length of time in clinical environment.
Alternative suggestions for volunteer engagement
The participants suggested a number of alternative
methods which could be considered for engaging volun-
teers to the study including grouped study inductions,
volunteer experience videos, as well as websites and
blogs. One participant shared their views on group-
orientated sessions to be used in recruitment:
P7: Yeah, I think group settings are actually very
good for generating discussion and people will ask
questions you haven’t thought of and you’ll ask ques-
tions they hadn’t thought of …
P7: … again, if you had a website you could have
stories you know about people and the effect that it
has on people’s lives.
Improving recruitment
Ideas suggested included use of internet technologies
such as email, weblinks and social media in combination
with traditional ‘word-of-mouth’ and radio methods.
Additional engagement that could reinforce recruitment
could include interactive resources such as quizzes and
automated pre-screening methods. Social media was
favoured by one participant:
P7: Facebook is one way that I know they’ve [other
researchers] tried.
Suggestions for location of sand fly biting and possible
scarring site
The sand fly biting site suggested by the research team
included the volar aspect of the forearm, close to the
antecubital fossa (i.e. elbow pit). Participants then dis-
cussed their favoured areas, as well as enquiring about
the relative propensity for scarring of the alternate areas.
Several participants described a choice of anatomical
areas as being an important factor in deciding to take
part, but also the acceptability of any scarring:
P7: It’s that thing about social acceptability is that
lots and lots of people have got those vaccination
scars on the tops of their arms and that’s just com-
pletely normal whereas a visible scar here it’s a bit,
it’s just sort of human beings our acceptance of
scars.
P5: I could make a suggestion you know our sug-
gested site is here but if you like you can have it sort
of elsewhere.
P1: So, you have a choice?
P5: Exactly, and ninety percent of the time they’ll
just go with what you suggest because they don’t
have a strong opinion they won’t care. But if they do
sort of feel very strongly, great they get to actually
feel in control.
Choice of treatments
The treatment options are varied in the treatment of
leishmaniasis, and participants were given the relative
merits and shortcomings of each option. Participants
agreed upon surgical excision as a possible method of
treatment above other therapies. For example, several
participants described their rationale for such a choice
including as a reassuring treatment and for the scientific
utility of having tissue that could be analysed by re-
searchers. Surgical excision is described here by partici-
pants as a ‘biopsy’:
P12: Would you think it was more reassuring to ex-
cise the lesion and use the ointment?...
… P9: Yes.
P1: So, if we kind of compromise and say from a
study point of view our first choice is to take a biopsy
so we can test it …
P3: I wouldn’t mind if I understood there was a
benefit. If it says you’ll have a biopsy and I had a
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large birthmark and the reason I wouldn’t want ex-
cision is because having that off was quite unpleas-
ant, but it was worth it for the biopsy results. I
wouldn’t have had it off as a cosmetic procedure. So,
I think if you’re advising people, we’re taking it off by
excision because we’re going to do this to it rather
than just for the sake of getting it
P7: So, a small biopsy is, if that’s part of the proto-
col. If you knew that was what you were signing up
to. I mean I would be, personally I would be more
than happy with that, you know, but that would be
if it was what I had signed up to …
Contacting the volunteer’s GP
Participants discussed the importance of confirming
medical background history from the CHIM volunteer’s
GP, and that it would actually be a reassuring practice,
as described by one participant:
P5: I think it’s good [contacting the volunteer’s GP]
because for example with vaccine history a lot of
people don’t necessarily know exactly what they had
vaccines for whereas you know that will be in their
medical records.
Length of time in the clinical environment
Given the possible risk of reaction to sand fly bite, par-
ticipants discussed that remaining in a clinical environ-
ment for continued observation post-sand fly biting
would be reassuring, although did not favour an ex-
tended observation period:
P9: … as long as the two hours would be reassuring
to me that, you know, most anaphylactic reactions
would happen within that time frame then that
would make me reassured and happy.
Overarching theme 3) motivations for involvement in
research Participants were asked about their motivations
for involvement in the consultation exercise and if that
translated into similar motivations for either the FLY-
BITE or the LEISH_Challenge studies. Three themes
were generated within this overarching theme which in-
cluded i) remuneration, ii) altruism/making a difference,
iii) and dual motivation.
Remuneration
For many participants it was acknowledged that the fi-
nancial aspect was an important draw for involvement in
any clinical research. One participant described this as a
boost to their income:
P5: … it’s a very time effective way of supplementing
their income. That’s why everyone I know took part in
them [i.e. clinical trials], chose to take part in them.
Altruism/making a difference
The renumeration for involvement was balanced by al-
truistic motivations for some participants. One of the
participants described how altruism would be an import-
ant factor for potential volunteers
P9: … I think there are a lot of people who want to get
involved [in clinical trials] to make a difference as well.
Dual motivation
Most participants voiced a mixture of motivations to be
an important draw in taking part in either the FLYBITE
study or LEISH_Challenge study, as discussed by some
of the participants:
P5: The altruism, it makes me feel better about tak-
ing part in it but it wouldn’t have been enough by it-
self.
P9: No, I think it’s very much both. I think a lot of
people are motivated by both of those things it’s like
I want to make a difference, I really want to make a
difference but oh that’s great if I actually get some
payment too that’s great. And I think one of the
things when you talk about the potential benefits of
the study I think you need to add on that one of the
potential benefits is you get to make a contribution,
you get to make a difference in helping us create a
model that will develop a vaccine that will change
and possibly save lives.
Discussion
Our adaptive approach to PI was effective in delivering
the objectives of the consultation group and informed
each of our proposed studies, FLYBITE and LEISH_
Challenge. Overall, the proposed studies were well re-
ceived by the PI consultation group, however this was
only after clarifications around the language used were
made, and on further debrief by clinical investigators.
Participants held a frank discussion about the literature
given in advance and made significant comments on the
need to include our plain language summary within the
body of any patient-facing material. Given the unique re-
search question posed by CHIM studies, the complexity
of neglected tropical diseases such as leishmaniasis and
the possible implications for invasive intervention, this is
a critical point within our research but also for clinical
research as whole. Studies must be accessible to individ-
uals, and often the impact of such interventions goes be-
yond those involved in studies themselves [30].
The concept of reflexivity in public engagement re-
search is an important entity in examining inherent
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biases of researchers [31]. It is an ongoing process of
evaluating the research experience and acknowledging
that team members may individually analyse and in-
terpret data based on their respective backgrounds
and personal experience of the research topic. Given
the complex nature of CHIM studies, reflexive prac-
tice is important in ensuring that participants with
limited prior scientific knowledge were appropriately
engaged and their opinions were allowed a platform.
The clinical research team had no prior experience of
CHIM studies, although have varied exposure to
leishmaniasis studies and clinical research more
broadly. The prior experience of clinical researchers
ranged from some limited prior involvement, to sig-
nificant input into clinical study design. The inde-
pendent health psychologist chair and analyst were
not involved directly in recruitment to the project but
have had significant experience in practicing reflexiv-
ity. This heterogenous make-up of the team helped to
therefore reduce research bias, and also reduce expec-
tations of the themes to be generated. Given the
unique mix of the research team, this was helpful in
ensuring an open and encouraging environment
where it was possible for research ideas to be openly
questioned by participants.
The most important impact of the PI consultation
group was the discussion of the treatment options posed.
There is no clear consensus for a single treatment option
for localised cutaneous leishmaniasis; it is mainly deter-
mined by species, local resources, experience of health-
care professionals and tolerability of treatment. After
discussion of potential treatments, participants unani-
mously supported surgical excision of any cutaneous
leishmaniasis lesion as the preferred treatment approach.
Once a lesion is well established, excision is not cur-
rently favoured as a treatment option for localised cuta-
neous leishmaniasis amongst clinicians. However, early
lesions are sometimes excised and tissue is examined as
part of the diagnostic process. Excision as a treatment
option in the context of the CHIM was therefore not
discussed as a possibility prior to PI, in part due to ex-
pected poor acceptability. Participants also suggested
that the cutaneous leishmaniasis lesion should be
allowed to develop to the smallest possible size that
could yield a positive identification of the cause whilst
being distinguishable from incidental non-parasitic
causes and also provide enough tissue material for ana-
lysis. These discussions concerning treatment options
prompted further discourse with clinical specialists, ex-
perienced in the care of patients with leishmaniasis, who
agreed with surgical excision as a valid method to ter-
minate lesions in the context of the study. This has now
been incorporated in the CHIM protocol, which has
been approved following ethical review. This is therefore
a significant change brought about by the public involve-
ment process.
The research had some limitations. Although we did
not record ethnicity as judged by participants them-
selves, it is an important issue more widely in research
[32] and investigators noted a lack of ethnic diversity
amongst our PI consultation group participants despite
advertising widely. Leishmaniasis is present in tropical
regions, typically low and middle incomes countries. It
could be argued that the lack of representation on the PI
panel may not be representative of a resource poor en-
vironment in an LMIC, although this PI consultation
group was specifically concerned with studies to be con-
ducted in the UK. Further public involvement work
might be required if the CHIM study is adopted in
LMICs. Skin colour can affect outcomes in several ways
with respect to leishmaniasis, and indeed one study sug-
gested that people of colour have increased morbidity
due to disparities in access to healthcare [33]. Further-
more differing skin phototypes may have differing re-
sponses to a Leishmania infection, resulting in more
scarring or other possible clinical sequelae such as
hyper- or hypopigmentation [34]. These issues may alter
health-seeking behaviour. A more ethnically diverse PI
group may have had greater awareness of the import-
ance of such issues. It was interesting however to note
that one of the participants commented that they had
‘mixed race children and my husband … he scars, you
know’ [see Additional file 1]. Additionally, the majority
of our participants were drawn from the local York area
and were educated to university level, although this was
not specifically recorded. York is considered one of the
least deprived regions of the UK [35] and therefore the
motivations for involvement in research may not reflect
the general population. We were unable to recruit a par-
ticipant who had had prior treatment for cutaneous
leishmaniasis or had resolved their infection without
treatment. However, the inclusion of such a patient may
have added an extra layer of complexity to the discus-
sion. The predominant cases of imported cutaneous
leishmaniases to the UK are caused by New World
Leishmania species that cause more protracted and ag-
gressive lesions that are generally more difficult to treat
than those caused by Leishmania major, the challenge
agent for use in our project [14]. Participants who had
undergone treatment for a species of Leishmania other
than our proposed challenge agent would have had a dif-
ferent experience of treatment [36]. However, we were
able to recruit participants of prior clinical research pro-
jects and a previous CHIM study participant.
Our research has some parallels with, and deviations
from, other studies concerned with PI in general, and
with respect to CHIM studies. It has been recognised for
many years that public involvement is imperative to
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good research, however its implications and usage has
been varied, dependent on setting, experience and local
guidance and infrastructure [37, 38]. Furthermore, the
literature suggests that where support for PI is strong,
the implementation of outcomes within research is often
weak [39]. This contrasts with our experience here,
where our research project has been shaped in ways
which would not have been possible without PI. A
prominent example of PI within CHIMs have been dis-
cussed more recently with the advent of a CHIM for
SARS-CoV-2, in order to test candidate vaccines [40,
41]. The themes generated within PI concerned with
such studies, and points of discussion were broadly simi-
lar with our study; namely, risk to volunteers, level of re-
muneration, support networks and clarity of information
[42]. The importance of CHIM studies being acceptable
to the public, even after research ethics committee ap-
proval, has been discussed at length, and is an approach
that we have mirrored here [43, 44]. This is demon-
strated by our planned use of public involvement after
our initial study, FLYBITE, and prior to our CHIM
study, LEISH_Challenge, in a process of continual re-
view. Further public involvement will take place at the
end of the project in order to establish this CHIM as a
standard model for use by researchers wishing to evalu-
ate candidate leishmaniasis vaccines (see Fig. 1). Others
have however importantly highlighted issues with par-
ticular respect to CHIM studies carried out in LMICs
[43]. Some studies also discuss motivations for inclusion
of volunteers in depth, characterizing the nature of altru-
ism in CHIM studies and the need for balancing this
with risk of the challenge agent [45]. One further im-
portant difference observed between our work here and
others described in the literature is the discussion
centred around treatment. Our PI activity involved par-
ticipants in the conversation about the choice of treat-
ment options to terminate the infection, something that
has not been observed elsewhere as far as the authors
can determine.
Conclusion
We describe here the first detailed description of
public involvement in controlled human infection re-
search for cutaneous leishmaniasis. The PI consult-
ation group session contributed not only to the
project literature and highlighted public perception to
study investigators, but also significantly impacted the
design and practical considerations of the studies.
Given the unique research question posed by con-
trolled human infection studies, and the ethical de-
bate surrounding them, the PI consultation group
meaningfully improved understanding of these issues.
We hope that this description will serve to improve
awareness of the public involvement process and en-
courage researchers to utilise such processes to in-
form and improve study design and delivery.
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